Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
US Department of Justice
McKinsey
Mallinckrodt
Chubb
Baxter
Boehringer Ingelheim
Johnson and Johnson
Julphar

Generated: June 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020699

« Back to Dashboard

NDA 020699 describes EFFEXOR XR, which is a drug marketed by Wyeth Pharms Inc and is included in one NDA. It is available from fourteen suppliers. Additional details are available on the EFFEXOR XR profile page.

The generic ingredient in EFFEXOR XR is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.
Summary for 020699
Tradename:EFFEXOR XR
Applicant:Wyeth Pharms Inc
Ingredient:venlafaxine hydrochloride
Patents:0
Therapeutic Class:Antidepressants
Formulation / Manufacturing:see details
Pharmacology for NDA: 020699
Suppliers and Packaging for NDA: 020699
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699 NDA Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. 0008-0833 N 0008-0833-03
EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699 NDA Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. 0008-0833 N 0008-0833-20

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 37.5MG BASE
Approval Date:Oct 20, 1997TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 75MG BASE
Approval Date:Oct 20, 1997TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 100MG BASE
Approval Date:Oct 20, 1997TE:RLD:No

Expired US Patents for NDA 020699

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-003 Oct 20, 1997 ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-003 Oct 20, 1997 ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-002 Oct 20, 1997 ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-004 Oct 20, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Healthtrust
Chubb
Cipla
Moodys
Citi
Boehringer Ingelheim
Dow
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.